Market closed
First Wave BioPharma Inc./$ENTO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About First Wave BioPharma Inc.
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Ticker
$ENTO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
2
ISIN
US33749P4081
Website
ENTO Metrics
BasicAdvanced
$2M
-
-$5.33
0.89
-
Price and volume
Market cap
$2M
Beta
0.89
52-week high
$0.90
52-week low
$0.32
Average daily volume
956K
Financial strength
Current ratio
3.031
Quick ratio
0.006
Long term debt to equity
0.102
Total debt to equity
0.243
Management effectiveness
Return on assets (TTM)
-21.16%
Return on equity (TTM)
-50.87%
Valuation
Price to book
-0.51
Price to tangible book (TTM)
-0.36
Price to free cash flow (TTM)
-0.156
Growth
Earnings per share change (TTM)
-88.87%
ENTO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for First Wave BioPharma Inc. stock?
First Wave BioPharma Inc. (ENTO) has a market cap of $2M as of May 14, 2025.
What is the P/E ratio for First Wave BioPharma Inc. stock?
The price to earnings (P/E) ratio for First Wave BioPharma Inc. (ENTO) stock is 0 as of May 14, 2025.
Does First Wave BioPharma Inc. stock pay dividends?
No, First Wave BioPharma Inc. (ENTO) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next First Wave BioPharma Inc. dividend payment date?
First Wave BioPharma Inc. (ENTO) stock does not pay dividends to its shareholders.
What is the beta indicator for First Wave BioPharma Inc.?
First Wave BioPharma Inc. (ENTO) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.